Martin Shkreli is an American former hedge fund manager and convicted felon.

Shkreli is the co-founder of the hedge funds;

1. 1. Elea Capital,

1. MSMB Capital Management and
2. MSMB Healthcare; the co-founder and former chief executive officer (CEO) of the pharmaceutical firms Retrophin and Turing Pharmaceuticals (now Vyera Pharmaceuticals); and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.

In September 2015, Shkreli was widely criticized when Turing obtained the manufacturing license for the antiparasitic drug Daraprim and raised its price from US$13.50 to $750 per pill.

In 2017, Shkreli was charged and convicted in federal court on two counts of securities fraud and one count of conspiring to commit securities fraud, unrelated to the Daraprim controversy.

Shkreli was sentenced to seven years in federal prison and up to $7.4 million in fines and in the civil case, he was fined a further $64.6 million to be given to victims nationwide.

In June 2017, Reuters reported that Shkreli had reported his net worth at $70 million following his arrest in 2015.